Abstract: The present invention provides compositions of modified pectin and methods for preparing and using them.

Abstract: The present invention provides compositions of modified pectin and methods for preparing and using them.

Abstract: The present invention provides compositions of modified pectin and methods for preparing and using them.

Abstract: The present invention provides compositions of modified pectin and methods for preparing and using them.

Abstract: The present invention provides compositions of modified pectin and methods for preparing and using them.

Abstract: The present invention provides compositions of modified pectin and methods for preparing and using them.

Abstract: The present invention provides compositions of modified pectin and methods for preparing and using them.

Abstract: The present invention provides compositions of modified pectin and for preparing and using them.

Abstract: Liquid interferon compositions having a pH between 4.0 and 7.2 are described. The compositions comprise interferon-beta and a stabilizing agent at between about 0.3% and 5% by weight which is an amino acid selected from the group consisting of acidic amino acids, arginine and glycine. If needed, salt is added to provide sufficient ionic strength. The liquid composition has not been previously lyophilized or previously cavitated. The liquid is preferably contained within a vessel having at least one surface in contract with the liquid that is coated with a material inert to adsorption of interferon-beta. A kit for parenteral administration of a liquid interferon formulation and a method for stabilizing liquid interferon compositions are also described.

Abstract: Devices and methods are provided for the storage and controlled release of a solid form of a drug. The device comprises a body portion; one or more reservoirs located in and defined by the body portion; a solid matrix which comprises a drug and which is contained in each of the one or more reservoirs; and one or more excipient materials dispersed throughout pores or interstices within the solid matrix and substantially filling any space not otherwise occupied by the solid matrix within each of the one or more reservoirs, wherein the excipient material enhances stability of the drug while stored in the one or more reservoirs or enhances release of the drug from each reservoir. In an alternative embodiment, the device provides for the storage and controlled exposure of a chemical sensor material.

Abstract: Devices and methods are provided for transdermal diagnostic sensing, alone or in combination with transdermal drug delivery. The device includes a substrate having a plurality of discrete reservoirs, each reservoir having at least one opening; contents disposed in the reservoirs, the contents of each reservoir including a diagnostic agent or a sensor for measuring an analyte; at least one discrete reservoir cap which cover said at least one opening; control means for disintegrating or permeabilizing the reservoir cap; means for transporting an analyte from the skin to said sensors and/or for transporting said diagnostic agent to the skin following release of said diagnostic agents from said reservoir; and means for securing the device to the skin of a patient.

Abstract: Devices and methods are provided for transdermal administration of a pharmaceutical agent to a patient in need thereof. The device includes a substrate, a plurality of discrete reservoirs in the substrate, one or more pharmaceutical agents stored in the reservoirs, discrete reservoir caps that prevent the pharmaceutical agent from passing out from the reservoirs until desired, control means for actuating release of the one or more pharmaceutical agents from one or more of the reservoirs by disintegrating or permeabilizing the reservoir caps, means for securing the device to the skin of the patient, and means for transporting the pharmaceutical agent to the skin following release from the one or more of the reservoirs. In another embodiment, the device is adapted for diagnostic sensing instead of or in addition to drug delivery.

Abstract: Liquid interferon compositions having a pH between 4.0 and 7.2 are described. The compositions comprise interferon-beta and a stabilizing agent at between about 0.3% and 5% by weight which is an amino acid selected from the group consisting of acidic amino acids, arginine and glycine. If needed, salt is added to provide sufficient ionic strength. The liquid composition has not been previously lyophilized or previously cavitated. The liquid is preferably contained within a vessel having at least one surface in contact with the liquid that is coated with a material inert to adsorption of interferon-beta. A kit for parenteral administration of a liquid interferon formulation and a method for stabilizing liquid interferon compositions are also described.

Abstract: Liquid interferon compositions having a pH between 4.0 and 7.2 are described. The compositions comprise interferon-beta and a stabilizing agent at between about 0.3% and 5% by weight which is an amino acid selected from the group consisting of acidic amino acids, arginine and glycine. If needed, salt is added to provide sufficient ionic strength. The liquid composition has not been previously lyophilized or previously cavitated. The liquid is preferably contained within a vessel having at least one surface in contact with the liquid that is coated with a material inert to adsorption of interferon-beta. A kit for parenteral administration of a liquid interferon formulation and a method for stabilizing liquid interferon compositions are also described.

Abstract: Liquid interferon compositions having a pH between 4.0 and 7.2 are described. The compositions comprise interferon-beta and a stabilizing agent at between about 0.3% and 5% by weight which is an amino acid selected from the group consisting of acidic amino acids, arginine and glycine. If needed, salt is added to provide sufficient ionic strength. The liquid composition has not been previously lyophilized or previously cavitated. The liquid is preferably contained within a vessel having at least one surface in contact with the liquid that is coated with a material inert to adsorption of interferon-beta. A kit for parenteral administration of a liquid interferon formulation and a method for stabilizing liquid interferon compositions are also described.

Abstract: A pump patch device is provided for drug delivery. The device may include a substrate having a plurality of discrete reservoirs, each reservoir having a reservoir opening; a drug disposed in the reservoirs; a pump for delivering a carrier fluid through or adjacent to the reservoir openings; a flow channel for receiving and combining the carrier fluid from the pump with the drug from the reservoirs to form a fluidized drug; and a needle for delivering the fluidized drug into the skin or another biological tissue of a patient. A device is provided for use in dialysis that includes a non-disposable module including a pump or pressure generator; and a disposable cassette operably connected to the pump or pressure generator and including a plurality of discrete reservoirs containing drug and sensors. A fluidics connection device is provided that includes a compression cold weld seal for a microfluidic via.

Abstract: Implantable medical devices and methods of use are provided for controlled drug delivery. The devices may include an elongated body dimensioned to facilitate minimally invasive and complete implantation into a patient, wherein the elongated body portion comprises a first, closed end portion, a second closed end portion and an intermediate portion disposed between and connected to the first closed end portion and the second closed end portion; two or more discrete reservoirs disposed in the elongated body portion, each reservoir having one or more openings; a drug formulation, which comprises at least one drug, disposed in the two more discrete reservoirs; and reservoir caps closing off the one or more openings of each reservoir, wherein release of the drug in vivo is controlled at least in part by the in vivo disintegration or permeabilization of the discrete reservoir caps.

Abstract: A method is provided for non-invasively detecting mechanical wear of a prosthetic device implanted in a patient, the method comprises using a non-invasive imaging technique to image the prosthetic device that includes a wear indicating composition; and detecting whether the wear indicating composition has been released from the prosthetic device, and, if so, the location, type, and/or amount thereof. The implant device includes a prosthetic device body having at least one outer surface area; at least one reservoir (e.g., a plurality of discretely spaced micro-reservoirs) in the device body; a wear indicator composition disposed in said at least one reservoir, wherein mechanical wear of the at least one outer surface area of the device body in vivo causes release of at least part of the wear indicator composition. The prosthetic device body may be one for replacement of a hip, a knee, a shoulder, an elbow, or a vertebra.

Abstract: Implantable prosthetic devices are provided for controlled drug delivery, for orthopedic and dental applications. The device may include a prosthetic device body having at least one outer surface area; two or more discrete reservoirs located in spaced apart positions across at least a portion of the outer surface area, the reservoirs formed with an opening at the surface of the device body and extending into the device body; and a release system disposed in the reservoirs which comprises at least one therapeutic or prophylactic agent, wherein following implantation into a patient the therapeutic or prophylactic agent is released in a controlled manner from the reservoirs. The prosthetic device body preferably is a joint prosthesis or part thereof, such as a hip prosthesis, a knee prosthesis, a vertebral or spinal disc prosthesis, or part thereof. Optional reservoir caps may further control release kinetics.

Abstract: Devices and methods are provided for transdermal administration of a pharmaceutical agent to a patient in need thereof. The device includes a substrate, a plurality of discrete reservoirs in the substrate, one or more pharmaceutical agents stored in the reservoirs, discrete reservoir caps that prevent the pharmaceutical agent from passing out from the reservoirs until desired, control means for actuating release of the one or more pharmaceutical agents from one or more of the reservoirs by disintegrating or permeabilizing the reservoir caps, means for securing the device to the skin of the patient, and means for transporting the pharmaceutical agent to the skin following release from the one or more of the reservoirs. In another embodiment, the device is adapted for diagnostic sensing instead of or in addition to drug delivery.